Tough targets sharpen performance at Roche Diagnostics
This article was originally published in Clinica
A couple of businesses are not yet meeting the threshold but they still have a chance so I will not name them." The tough but fair approach of Heino von Prondzynski, head of Roche Diagnostics, leaves the company's staff in no doubt as to what is expected of them, and this approach is vindicated by the continuing strong performance of the world's largest in vitro diagnostics organisation.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.